New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials

Molecular Therapy

Volumn 19, Issue 11, 2011, Pages 1942-1949

  Vandermeulen, Gaëlle ^a   Marie, Corinne ^b,c,d,e   Scherman, Daniel ^b,c,d,e   Préat, Véronique ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Laboratoire de Pharmacologie Chimique et Génétique et d'Imagerie   (France)

^c Centre National de la Recherche Scientifique   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; DNA VACCINE; FIBROBLAST GROWTH FACTOR; GLYCINE; GLYCINE HYDROXYMETHYLTRANSFERASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LACK ANTIGEN; LEISHMANIA VACCINE; PARASITE ANTIGEN; PLASMID DNA; PROTEIN E7; TRANSFER RNA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; AUXOTROPHY; BACTERIAL STRAIN; BIOSAFETY; BLA GENE; CELL DENSITY; CPG ISLAND; ENZYME DEGRADATION; ENZYME INACTIVATION; FABI GENE; GENE; GENE CASSETTE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GLYA GENE; HORIZONTAL GENE TRANSFER; HUMAN; IN VIVO GENE TRANSFER; INNATE IMMUNITY; MULTIDRUG RESISTANCE; NONHUMAN; NONVIRAL GENE THERAPY; NPTII GENE; PLASMID; PROKARYOTE; PROTEIN MOTIF; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; RNA TRANSLATION; SAFETY; TITRIMETRY; TRANSGENE; VACCINE PRODUCTION;

EID: 80555150705     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.182     Document Type: Review

References (68)

1. The Journal of Gene Medicine Clinical Trial site (2011). www.wiley.com/ legacy/wileychi/genmed/clinical/
2. Wolff, JA, Malone, RW, Williams, P, Chong, W, Acsadi, G, Jani, A et al. (1990). Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1): 1465-1468.
3. Friehs, K (2004). Plasmid copy number and plasmid stability. Adv Biochem Eng Biotechnol 86: 47-82.
4. Summers, D (1998). Timing, self-control and a sense of direction are the secrets of multicopy plasmid stability. Mol Microbiol 29: 1137-1145. (Pubitemid 28408837)
5. European Pharmacopeia 7.0 (2011), 5.14. Gene transfer medical products for human use: 648.
6. World Health Organization. Guidelines for assuring the quality and nonclinical safety evaluation of DNA vaccines (2005).http://www.who.int/ biological/publications/trs/areas/vaccines/dna/Annex%201-DNA%20vaccines.pdf
7. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer Medicinal Products http://www.ema.europa.eu/docs/en-GB/document-library/ Scientifc-guideline/2009/10/WC500003977.pdf (2001).
8. US Food and Drug Administration. Guidance for human somatic cell therapy and gene therapy (1998).http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ ucm081670.pdf
9. Nicolau, DP (2011). Current challenges in the management of the infected patient. Curr Opin Infect Dis 24 Suppl 1: S1-10.
10. Alanis, AJ (2005). Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res 36: 697-705. (Pubitemid 41436239)
11. Solensky, R (2003). Hypersensitivity reactions to beta-lactam antibiotics. Clin Rev Allergy Immunol 24: 201-220.
12. Rozkov, A, Avignone-Rossa, CA, Ertl, PF, Jones, P, O'Kennedy, RD, Smith, JJ et al. (2004). Characterization of the metabolic burden on Escherichia coli DH1 cells imposed by the presence of a plasmid containing a gene therapy sequence. Biotechnol Bioeng 88: 909-915. (Pubitemid 39664616)
13. Cunningham, DS, Koepsel, RR, Ataai, MM and Domach, MM (2009). Factors affecting plasmid production in Escherichia coli from a resource allocation standpoint. Microb Cell Fact 8: 27.
14. Escriou, V, Ciolina, C, Helbling-Leclerc, A, Wils, P and Scherman, D (1998). Cationic lipid-mediated gene transfer: analysis of cellular uptake and nuclear import of plasmid DNA. Cell Biol Toxicol 14: 95-104. (Pubitemid 28123599)
15. Escriou, V, Carrière, M, Bussone, F, Wils, P and Scherman, D (2001). Critical assessment of the nuclear import of plasmid during cationic lipid-mediated gene transfer. J Gene Med 3: 179-187. (Pubitemid 33685445)
16. Kreiss, P, Cameron, B, Darquet, AM, Scherman, D and Crouzet, J (1998). Production of a new DNA vehicle for gene transfer using site-specifc recombination. Appl Microbiol Biotechnol 49: 560-567. (Pubitemid 28267248)
17. Kreiss, P, Cameron, B, Rangara, R, Mailhe, P, Aguerre-Charriol, O, Airiau, M et al. (1999). Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer effciency. Nucleic Acids Res 27: 3792-3798. (Pubitemid 29454426)
18. Bloquel, C, Fabre, E, Bureau, MF and Scherman, D (2004). Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J Gene Med 6 Suppl 1: S11-S23. (Pubitemid 40228013)
19. Gardlik, R, Behuliak, M, Palffy, R, Celec, P and Li, CJ (2011). Gene therapy for cancer: bacteria-mediated anti-angiogenesis therapy. Gene Ther 18: 425-431.
20. Pálffy, R, Gardlík, R, Hodosy, J, Behuliak, M, Resko, P, Radvánský, J et al. (2006). Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Ther 13: 101-105. (Pubitemid 43039902)
21. Krieg, AM (2002). CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760. (Pubitemid 34293438)
22. Takaoka, A, Wang, Z, Choi, MK, Yanai, H, Negishi, H, Ban, T et al. (2007). DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448: 501-505. (Pubitemid 47123520)
23. Vidal, L, Pinsach, J, Striedner, G, Caminal, G and Ferrer, P (2008). Development of an antibiotic-free plasmid selection system based on glycine auxotrophy for recombinant protein overproduction in Escherichia coli. J Biotechnol 134: 127-136.
24. Dong, WR, Xiang, LX and Shao, JZ (2010). Novel antibiotic-free plasmid selection system based on complementation of host auxotrophy in the NAD de novo synthesis pathway. Appl Environ Microbiol 76: 2295-2303.
25. Hägg, P, de Pohl, JW, Abdulkarim, F and Isaksson, LA (2004). A host/plasmid system that is not dependent on antibiotics and antibiotic resistance genes for stable plasmid maintenance in Escherichia coli. J Biotechnol 111: 17-30. (Pubitemid 38757817)
26. Soubrier, F, Cameron, B, Manse, B, Somarriba, S, Dubertret, C, Jaslin, G et al. (1999). pCOR: a new design of plasmid vectors for nonviral gene therapy. Gene Ther 6: 1482-1488. (Pubitemid 29396737)
27. Soubrier, F, Laborderie, B and Cameron, B (2005). Improvement of pCOR plasmid copy number for pharmaceutical applications. Appl Microbiol Biotechnol 66: 683-688. (Pubitemid 40385632)
28. Marie, C, Vandermeulen, G, Quiviger, M, Richard, M, Préat, V and Scherman, D (2010). pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells. J Gene Med 12: 323-332.
29. Bukowski, M, Rojowska, A and Wladyka, B (2011). Prokaryotic toxin-antitoxin systems-the role in bacterial physiology and application in molecular biology. Acta Biochim Pol 58: 1-9.
30. Pecota, DC, Kim, CS, Wu, K, Gerdes, K and Wood, TK (1997). Combining the hok/sok, parDE, and pnd postsegregational killer loci to enhance plasmid stability. Appl Environ Microbiol 63: 1917-1924. (Pubitemid 27194855)
31. Van Melderen, L (2002). Molecular interactions of the CcdB poison with its bacterial target, the DNA gyrase. Int J Med Microbiol 291: 537-544. (Pubitemid 34206834)
32. Szpirer, CY and Milinkovitch, MC (2005). Separate-component-stabilization system for protein and DNA production without the use of antibiotics. BioTechniques 38: 775-781. (Pubitemid 40647046)
33. Peubez, I, Chaudet, N, Mignon, C, Hild, G, Husson, S, Courtois, V et al. (2010). Antibiotic-free selection in E. coli: new considerations for optimal design and improved production. Microb Cell Fact 9: 65.
34. Williams, SG, Cranenburgh, RM, Weiss, AM, Wrighton, CJ, Sherratt, DJ and Hanak, JA (1998). Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26: 2120-2124. (Pubitemid 28291755)
35. Cranenburgh, RM, Hanak, JA, Williams, SG and Sherratt, DJ (2001). Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. Nucleic Acids Res 29: E26.
36. Luke, J, Carnes, AE, Hodgson, CP and Williams, JA (2009). Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system. Vaccine 27: 6454-6459.
37. Luke, JM, Vincent, JM, Du, SX, Gerdemann, U, Leen, AM, Whalen, RG et al. (2011). Improved antibiotic-free plasmid vector design by incorporation of transient expression enhancers. Gene Ther 18: 334-343.
38. Mairhofer, J, Cserjan-Puschmann, M, Striedner, G, Nöbauer, K, Razzazi-Fazeli, E and Grabherr, R (2010). Marker-free plasmids for gene therapeutic applications-lack of antibiotic resistance gene substantially improves the manufacturing process. J Biotechnol 146: 130-137.
39. Xu, HH, Real, L and Bailey, MW (2006). An array of Escherichia coli clones over-expressing essential proteins: a new strategy of identifying cellular targets of potent antibacterial compounds. Biochem Biophys Res Commun 349: 1250-1257. (Pubitemid 44419612)
40. Goh, S and Good, L (2008). Plasmid selection in Escherichia coli using an endogenous essential gene marker. BMC Biotechnol 8: 61.
41. Mayrhofer, P, Schleef, M and Jechlinger, W (2009). Use of minicircle plasmids for gene therapy. Methods Mol Biol 542: 87-104.
42. Gill, DR, Pringle, IA and Hyde, SC (2009). Progress and prospects: the design and production of plasmid vectors. Gene Ther 16: 165-171.
43. Darquet, AM, Cameron, B, Wils, P, Scherman, D and Crouzet, J (1997). A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther 4: 1341-1349. (Pubitemid 28004593)
44. Darquet, AM, Rangara, R, Kreiss, P, Schwartz, B, Naimi, S, Delaère, P et al. (1999). Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther 6: 209-218. (Pubitemid 29089919)
45. Bigger, BW, Tolmachov, O, Collombet, JM, Fragkos, M, Palaszewski, I and Coutelle, C (2001). An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J Biol Chem 276: 23018-23027.
46. Chen, ZY, He, CY and Kay, MA (2005). Improved production and purifcation of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 16: 126-131. (Pubitemid 40250338)
47. Kay, MA, He, CY and Chen, ZY (2010). A robust system for production of minicircle DNA vectors. Nat Biotechnol 28: 1287-1289.
48. Mayrhofer, P, Blaesen, M, Schleef, M and Jechlinger, W (2008). Minicircle-DNA production by site specifc recombination and protein-DNA interaction chromatography. J Gene Med 10: 1253-1269.
49. Bloquel, C, Bessis, N, Boissier, MC, Scherman, D and Bigey, P (2004). Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum Gene Ther 15: 189-201. (Pubitemid 38210533)
50. Saidenberg-Kermanac'h, N, Bessis, N, Deleuze, V, Bloquel, C, Bureau, M, Scherman, D et al. (2003). Effcacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. J Gene Med 5: 164-171.
51. Pradat, P F, Finiels, F, Kennel, P, Naimi, S, Orsini, C, Delaere, P et al. (2001). Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer. Hum Gene Ther 12: 367-375. (Pubitemid 32186649)
52. Fabre, EE, Bigey, P, Beuzard, Y, Scherman, D and Payen, E (2008). Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment. Genet Vaccines Ther 6: 10.
53. Witzenbichler, B, Mahfoudi, A, Soubrier, F, Le Roux, A, Branellec, D, Schultheiss, HP et al. (2006). Intramuscular gene transfer of fbroblast growth factor-1 using improved pCOR plasmid design stimulates collateral formation in a rabbit ischemic hindlimb model. J Mol Med 84: 491-502. (Pubitemid 43801328)
54. Caron, A, Michelet, S, Caron, A, Sordello, S, Ivanov, MA, Delaère, P et al. (2004). Human FGF-1 gene transfer promotes the formation of collateral vessels and arterioles in ischemic muscles of hypercholesterolemic hamsters. J Gene Med 6: 1033-1045. (Pubitemid 40232986)
55. Comerota, AJ, Throm, RC, Miller, KA, Henry, T, Chronos, N, Laird, J et al. (2002). Naked plasmid DNA encoding fbroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35: 930-936. (Pubitemid 44718562)
56. Nikol, S, Baumgartner, I, Van Belle, E, Diehm, C, Visoná, A, Capogrossi, MC et al.; TALISMAN 201 investigators. (2008). Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 16: 972-978. (Pubitemid 351587109)
57. Mwau, M, Cebere, I, Sutton, J, Chikoti, P, Winstone, N, Wee, EG et al. (2004). A human immunodefciency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specifc T-cell responses by DNA and recombinant modifed vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85(Pt 4): 911-919. (Pubitemid 38489556)
58. Hanke, T and McMichael, AJ (2000). Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6: 951-955.
59. Wee, EG, Patel, S, McMichael, AJ and Hanke, T (2002). A DNA/MVA-based candidate human immunodefciency virus vaccine for Kenya induces multi-specifc T cell responses in rhesus macaques. J Gen Virol 83(Pt 1): 75-80. (Pubitemid 34030812)
60. Ohlschläger, P, Pes, M, Osen, W, Dürst, M, Schneider, A, Gissmann, L et al. (2006). An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specifc T cell response. Vaccine 24: 2880-2893.
61. Ramos, I, Alonso, A, Peris, A, Marcen, JM, Abengozar, MA, Alcolea, PJ et al. (2009). Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection. Vaccine 27: 6695-6703.
62. Daugimont, L, Vandermeulen, G, Defresne, F, Bouzin, C, Mir, LM, Bouquet, C et al. (2011). Antitumoral and antimetastatic effect of antiangiogenic plasmids in B16 melanoma: Higher effciency of the recombinant disintegrin domain of ADAM 15. Eur J Pharm Biopharm 78: 314-319.
63. Huang, M, Chen, Z, Hu, S, Jia, F, Li, Z, Hoyt, G et al. (2009). Novel minicircle vector for gene therapy in murine myocardial infarction. Circulation 120(11 Suppl): S230-S237.
64. Stenler, S, Andersson, A, Simonson, OE, Lundin, KE, Chen, ZY, Kay, MA et al. (2009). Gene transfer to mouse heart and skeletal muscles using a minicircle expressing human vascular endothelial growth factor. J Cardiovasc Pharmacol 53: 18-23.
65. Chen, ZY, He, CY, Ehrhardt, A and Kay, MA (2003). Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 8: 495-500. (Pubitemid 37161471)
66. Wu, J, Xiao, X, Zhao, P, Xue, G, Zhu, Y, Zhu, X et al. (2006). Minicircle-IFNgamma induces antiproliferative and antitumoral effects in human nasopharyngeal carcinoma. Clin Cancer Res 12: 4702-4713. (Pubitemid 44297824)
67. Chang, CW, Christensen, LV, Lee, M and Kim, SW (2008). Effcient expression of vascular endothelial growth factor using minicircle DNA for angiogenic gene therapy. J Control Release 125: 155-163. (Pubitemid 50008037)
68. Zhang, X, Epperly, MW, Kay, MA, Chen, ZY, Dixon, T, Franicola, D et al. (2008). Radioprotection in vitro and in vivo by minicircle plasmid carrying the human manganese superoxide dismutase transgene. Hum Gene Ther 19: 820-826.